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In Vivo: A Possible Role for Its Antipsoriatic Effect?
Melissa Garcı´a-Caballero1,3, Manuel Marı´-Beffa2,4, Miguel A´. Medina1,3 and Ana R. Quesada1,3
The fumaric acid esters (FAEs) have been used for the oral treatment of psoriasis for some 50 years. Given that a
persistent and maintained angiogenesis is associated with several cutaneous diseases, including psoriasis, we
sought in our study to gain further insight into their mechanism of action by investigating whether FAEs are able
to interfere with angiogenesis mechanisms. Our results demonstrate that dimethylfumarate (DMF) inhibits
certain functions of endothelial cells, namely, differentiation, proliferation, and migration. This activity was not
exhibited by similar concentrations of monomethylfumarate or fumaric acid. Our data indicate that DMF
inhibits the growth of transformed and nontransformed cells in a dose-dependent manner. The growth-
inhibitory effect exerted by this compound on proliferating endothelial cells could be due, at least in part, to an
induction of apoptosis. Inhibition by DMF of the mentioned essential steps of in vitro angiogenesis is consistent
with the observed inhibition of in vivo angiogenesis, substantiated using chick chorioallantoic membrane and
live fluorescent zebrafish embryo neovascularization assays. The antiangiogenic activity of DMF may contribute
to the antipsoriatic, antitumoral, and antimetastatic activities of this compound and suggests its potential in the
treatment of angiogenesis-related malignancies.
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INTRODUCTION
Fumaria officinalis, a plant rich in fumaric acid (FA), has been
in use as treatment for skin complaints since the seventeenth
century. The fumaric acid ester (FAE) dimethylfumarate (DMF)
and its metabolite monomethylfumarate (MMF) have been used
for the oral treatment of psoriasis for some 50 years. Since
its official registration in 1994, the commercially available
FAE preparation Fumaderm (Fumedica, Herne, Germany), an
empirically composed mixture of DMF with calcium, magne-
sium, and zinc salts of ethylhydrogen fumarate, has become the
leading oral systemic therapy for moderate to severe psoriasis
in Germany (Mrowietz and Asadullah, 2005). Clinical studies,
although limited in number, indicate that the efficacy of FAEs in
psoriasis is high, with favorable long-term safety and clinical-
efficacy profiles and relatively low toxicity (Brewer and Rogers,
2007). More recently, interest in the pharmacologic potential of
FAEs has been extended to the treatment of neoplastic skin
diseases. DMF has been reported to reduce melanoma growth
and metastasis in murine models (Loewe et al., 2006; Yamazoe
et al., 2009), as well as to enhance the in vivo antitumoral
activity of the alkylating agent dacarbazine (Valero et al., 2010).
The mechanism of action of FAEs is not yet fully understood.
In most biological assays, DMF exerts pharmacodynamic
effects that are more potent than those of MMF. In vitro studies
have revealed that DMF inhibits the expression of adhesion
molecules by endothelial cells (Loewe et al., 2002) and human
leukocytes, affecting their rolling behavior in vivo and therefore
the initial step of leukocyte extravasation (Rubant et al., 2008).
It has been shown that DMF selectively prevents the nuclear
translocation of cytoplasmic NF-kB (Loewe et al., 2001, 2002)
and NF-kB transactivation by the p38 mitogen-activated
protein kinase and the downstream kinases mitogen- and
stress-activated protein kinases 1 and 2 (Gesser et al., 2007).
The subsequent inhibition of NF-kB-induced gene transcription
may explain several of the in vitro effects reported for DMF on
several cell types, including the inhibition of the differentiation
of dendritic cells (Zhu and Mrowietz, 2001), induction of apop-
tosis (Treumer et al., 2003; Loewe et al., 2006), and inhibition of
the production of proinflammatory cytokines (Ockenfels et al.,
1998). Recent results suggest that DMF downregulates cytokine
secretion by inhibiting not only NF-kB but also a wider range
of NF-kB-linked signaling proteins (Seidel et al., 2009). A more
detailed understanding of the mode of action of FAEs might lead
to the identification of promising new drug targets.
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Angiogenesis is the generation of new capillaries via the
sprouting pre-existing microvessels. In health, vessel prolifera-
tion is under stringent control and occurs only during
embryonic development, endometrial regulation, reproductive
cycle, and wound repair. By contrast, persistent and deregu-
lated angiogenesis is related to diseases such as proliferative
retinopathies, psoriasis, and rheumatoid arthritis, and it seems
to be essential for tumor growth and metastasis (Carmeliet,
2005). For this reason, angiogenesis inhibition has attracted
broad attention in the field of pharmacological research.
Although angiogenesis research has been driven mainly by the
role played by this neovascularization mechanism in tumor
growth, invasion, and metastasis, the growing knowledge
regarding the involvement of angiogenic factors in seemingly
unrelated diseases suggests that angiogenesis can be consid-
ered an organizing principle in drug discovery, permitting
connections between unrelated phenomena and enabling the
development of therapeutics for one disease to facilitate the
development of therapeutics for others (Folkman, 2007).
Persistent and maintained angiogenesis is associated with
several cutaneous diseases, including psoriasis (Fried and
Arbiser, 2008). Microvascular changes such as increased
permeability, dilatation, and tortuosity of vessels—are already
evident in early stages of the evolution of a psoriatic plaque
(Heidenreich et al., 2009; Henno et al., 2010). An increasing
number of angiogenesis modulators, including vascular en-
dothelial growth factor, seem to have significant roles in the
pathophysiology and may even account for the maintenance of
the chronic inflammatory state (Lowes et al. 2007). Several
antiangiogenesis strategies are currently being explored for the
treatment of psoriasis, either by systemic use or by topical
application (Schonthaler et al., 2009; Abe et al., 2010).
The possibility that the mechanism of action of some
systemic therapies currently used for the treatment of
psoriasis could be related to an interference in the angiogenic
process cannot be discarded. In this study, we investigated
the antiangiogenic activity of the antipsoriatic FAEs. To our
knowledge, the results presented here are the first experi-
mental evidence showing that DMF is a potent inhibitor of
angiogenesis in vitro and in vivo. The observed antiangio-
genic activity of DMF could help to explain the antipsoriatic
activity of FAEs and suggest the benefits of further character-
ization of their pharmacological potential for the treatment of
other angiogenesis-related pathologies.
RESULTS
DMF inhibits the growth of endothelial and tumor cells
Angiogenesis involves local proliferation of endothelial cells.
Figure 1a shows that DMF inhibits the proliferation of actively
growing endothelial cells in a dose–response manner. MMF
and FA did not affect endothelial cell growth when tested
at 200mM (data not shown). Data obtained with non-
endothelial cell lines show that DMF is not a specific
inhibitor of endothelial cell growth, as the half-maximal
inhibitory concentration (IC50) values of this antiproliferative
effect on endothelial cells (bovine aortic endothelial cells
(BAECs) and human umbilical vein endothelial cells
(HUVECs)) were in the same range of those obtained with
human fibroblasts (NIH3T3). Moreover, lower IC50 values
were obtained with tumor cells (human fibrosarcoma
HT-1080, human breast carcinoma MDAMB231, human
colon adenocarcinoma HT29, and human osteosarcoma
U2OS), suggesting a preferential activity of the compound
on transformed cell lines (Figure 1b).
DMF inhibits capillary tube formation by endothelial cells
The final event during angiogenesis is the organization of
endothelial cells in a three-dimensional network of tubes. As
shown in Figure 2a, in vitro, endothelial cells plated
on Matrigel align themselves, forming cords that are already
evident a few hours after plating. DMF was able to significantly
inhibit the BAEC and HUVEC alignment and cord formation at
25 and 10mM, respectively. Complete inhibition of endothelial
morphogenesis on Matrigel was obtained at 100mM DMF for
BAECs and 50mM DMF for HUVECs (Figure 2a and b). The
DMF concentrations required to inhibit the differentiation of
BAECs and HUVECs did not affect their viability after 7 hours
(results not shown). MMF and FA did not significantly block
tube formation by BAECs when added at 200mM. Only partial
inhibition of HUVEC tubulogenesis was observed at 200mM
MMF or FA, indicating that DMF is the most active compound
in this in vitro assay of angiogenesis (Figure 2b).
DMF inhibits the migratory capability of endothelial cells
Angiogenesis involves the acquisition by endothelial cells
of the capability to migrate through extracellular matrix.
Our data indicate that DMF produced a dose-dependent
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Figure 1. Dimethylfumarate (DMF) inhibits the growth of endothelial and
tumor cells. (a) Representative dose-response curves showing the effect of
DMF on the in vitro growth of endothelial cells (human umbilical vein
endothelial cells (HUVECs) and bovine aortic endothelial cells (BAECs)),
human fibroblasts (NIH3T3), and tumor cells (HT1080, MDAMB231, HT29,
and U2OS). Cell survival is represented as a percentage of control cell growth
in cultures containing no drug. Each point represents the mean of
quadruplicates; SD values were always o10% of the mean values and are
omitted for clarity. (b) Half-maximal inhibitory concentration (IC50) values
calculated from dose-response curves as the concentration of DMF yielding
50% of control cell survival. They are expressed as means±SD of three
independent experiments with quadruplicate samples each.
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Figure 2. Effect of fumaric acid esters (FAEs) on endothelial tube formation and cell migration in vitro. (a) Representative images of endothelial cells treated
with FAEs. Bovine aortic endothelial cells (BAECs) and human umbilical vein endothelial cells (HUVECs) seeded on Matrigel formed tubes (left panels).
Dimethylfumarate (DMF) inhibited endothelial cell tubulogenesis in vitro at nontoxic doses. Monomethylfumarate (MMF) or fumaric acid (FA) only partially
inhibited HUVEC morphogenesis on Matrigel, with no effect on BAECs, at the assayed concentration. Cells were photographed 7hours after seeding under an
inverted microscope (bar¼ 100mm), and the number of tubule-like structures was counted and averaged. (b) Percentages of tubular-like structures are expressed
as mean±SD of three to five independent experiments, **Po0.001, #Po0.05 versus control. (c) Confluent cell monolayers were wounded and fresh culture
medium was added in either the absence or presence of the indicated concentrations of the tested compound. Photographs were taken at the beginning of the
assay and after indicated times of incubation. Left panels show representative pictures of the effect of DMF on BAEC migration (bar¼ 200mm). The regrowth of
BAECs, HUVECs, or NIH3T cells into the cell-free area was measured after 7 hours and percentages of recovered area are expressed as mean±SD of three
independent experiments (right panel), *Po0.01, #Po0.05 versus control.
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inhibition of the migratory capability of endothelial cells
(BAECs and HUVECs; Figure 2c and Supplementary Figure
S1a online). Similar concentrations of FA or MMF did not
exert this inhibitory effect on the migration of BAECs
(Supplementary Figure S1b online). The effect of DMF on
the migratory activity of human fibroblasts (NIH3T3) was less
remarkable (Figure 2c and Supplementary Figure S1a online).
DMF does not inhibit the kinase activity of VEGFR2
Vascular endothelial growth factor receptor 2 (VEGFR2, KDR,
Flk-1) is a major receptor for VEGF-induced signaling in
endothelial cells. Upon ligand binding, VEGFR2 undergoes
autophosphorylation and becomes activated. Because the
kinase activity of VEGFR2 is the molecular target of a number
of clinically successful angiogenesis inhibitors, we explored
the effect of FAEs on this activity by means of an in vitro assay
that directly measures the enzymatic activity of the human
recombinant VEGF receptor kinase 2 on a biotinylated
substrate. Our results showed that incubation with DMF, or
MMF or FA, at 200mM exerted no effect on the kinase activity
of human VEGFR2 (data not shown).
DMF induces apoptosis in endothelial cells in vitro
As a first approach to determine whether DMF could induce
apoptosis in endothelial cells, nuclear morphology was
investigated in BAECs after 14 hours of treatment with
various concentrations of this compound. Figure 3a shows
that 100 and 200mM DMF induced chromatin condensation
in proliferating BAECs, suggesting that DMF could induce
apoptosis on endothelial cells.
To confirm this assessment, cell cycle analysis was
performed in DMF-treated BAECs after propidium iodide
staining. Flow cytometric analysis showed that DMF sig-
nificantly increased apoptotic sub-G1 cells in a concentra-
tion-dependent manner. Thus, after treatment with DMF
100mM for 14 hours, apoptotic cells were increased 10-fold
compared with control (Figure 3b). Using the TUNEL assay as
another method to detect apoptosis, DMF was shown to
induce DNA fragmentation in proliferating BAECs (Figure 3c).
Similar results were obtained in proliferating HUVECs
(Supplementary Figure S2a online). By contrast, no significant
induction of apoptosis was observed in nonproliferating
quiescent BAECs (Supplementary Figure S2b online).
To determine whether caspases were activated as a result
of DMF treatment, we used a caspase-3 substrate DEVD-
AMC that is cleaved to a fluorescent product by caspase-3
and other caspases with similar substrate cleavage sequences.
As shown in Figure 3d, the ‘‘effector caspase’’-3 was
significantly activated in proliferating BAECs after treatment
with DMF. Thus, the results show that caspase activation
occurred in a pattern that is consistent with the DNA
fragmentation and the morphological evidence of endothelial
apoptosis following treatment with DMF. The results demon-
strating the in vitro induction of apoptosis by DMF are
reinforced by those showing an endothelial apoptosis
induction in vivo by this compound in the in vivo quail
chorioallantoic membrane (CAM) assay (Supplementary
Methods and Supplementary Figure S3 online).
DMF inhibits in vivo angiogenesis in the chick CAM and
zebrafish embryo assays
The CAM assay was used to determine the ability of DMF to
inhibit angiogenesis in vivo. In controls, blood vessels formed
a dense and spatially oriented, leaf-like branching network
composed of vascular structures of progressively smaller
diameter as they branch (Figure 4a, left panel). Table 1
summarizes the evaluation of the in vivo inhibition of
angiogenesis in the CAM assay by DMF. Treatment with
DMF caused a dose-dependent antiangiogenic effect, which
was observed as an inhibition of the ingrowth of new
vessels in the area covered by the methylcellulose discs. The
peripheral vessels (relative to the position of the disc) grew
centrifugally, avoiding the treated area, where a decrease
in the vascular density could be observed (Figure 4a,
right panel).
A zebrafish model system was also used to determine
the effect of DMF on in vivo angiogenesis. The transparency
and external development of the zebrafish embryo and
the ability to produce tissue-specific germline transgenic
fish expressing enhanced green fluorescent protein (EGFP)
make this organism an ideal system with which to
visualize the formation of the embryonic vasculature (Lawson
and Weinstein, 2002). Different concentrations of DMF were
incubated with embryos from a transgenic (TG(fli1:EGFP)y1)
zebrafish line that carries a 15-kb promoter of the trans-
cription factor friend leukemia virus integration-1 (fli-1),
which drives the GFP expression in the endothelium.
As shown in Table 1, the systemic exposure of DMF exerted
a dose–response inhibitory effect on the developmental
angiogenesis in zebrafish. During development of the
zebrafish, intersegmental vessels sprout and grow upward
from the aorta, and then the tips join by anastomosis to
form a dorsal vein (Figure 4b left panel). Our results show
that DMF inhibited the zebrafish intersegmental blood
vessel growth and angiogenesis, although the embryos
remained viable during the 24-hour period of the study
and overall morphology was similar to control embryos,
indicating that development was unaffected and also
indicating a low toxicity of this compound (Figure 4b
right panel).
The inhibition of blood circulation through the interseg-
mental vessels after a 24-hour incubation with DMF was
further confirmed by recording the blood flow. As can be
observed in Supplementary Movie S1 online, there was a
continuous flow of red blood cells through the intersegmental
vessels in the control zebrafish, treated with the vehicle
alone. Nevertheless, when the embryos were treated with
10 mM DMF, the circulation of blood cells through the
intersegmental vessel was slower than that of the control
embryos (Supplementary Movie S2 online), and a complete
lack of circulation with a beating heart was observed when
the embryos were treated with 25 mM DMF (Supplementary
Movie S3 online). In all cases, the blood flow through the
aorta and posterior cardinal vein was unaffected. These
results are in agreement with those obtained with the CAM
assay and indicate that DMF is a potent inhibitor of in vivo
angiogenesis.
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DISCUSSION
The FAEs have been used for the oral treatment of psoriasis
for some 50 years. Because psoriasis is an angiogenesis-
related pathology, and our aim was to gain further insight into
the FAEs’ mechanism of action, we sought to determine
whether FAEs are able to interfere with angiogenesis.
Knowledge of the sequence of events required for
neovascularization and the availability of cultured endothe-
lial cells have allowed for the development and use of in vitro
assays to model the different steps of the angiogenesis process
and to expedite the discovery of angiogenesis inhibitors.
Insofar as a factor could inhibit one or several of these key
events in vitro, it is a candidate for the inhibition of
angiogenesis in vivo (Quesada et al., 2006).
DMF inhibits the growth of nontransformed and trans-
formed cells in a dose-dependent manner. The IC50 of this
activity is similar for endothelial cells and normal fibroblasts,
indicating that DMF is not a selective inhibitor of endothelial
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Figure 3. Dimethylfumarate (DMF) induces endothelial cell apoptosis. (a) Effect of DMF on endothelial nuclear morphology. Bovine aortic endothelial cells
(BAECs) were grown on covers, treated with the indicated concentrations of DMF for 14 hours, fixed with formalin, stained with Hoechst, and mounted on
slides, and nuclei were observed under a fluorescence microscope (bar¼50 mm). (b) Effect of DMF on endothelial cell cycle distribution. BAECs were exposed
for 14 hours to DMF at the indicated concentrations and stained with propidium iodide, and percentages of subG1, G1, and S/G2/M cells were determined using
a MoFlo DakoCytomation (Fort Collins, CO) cytometer. One representative experiment of two is shown with superimposable results. (c) Effect of DMF on DNA
fragmentation in proliferating BAE cells. BAECs, grown to 75% confluency on eight-well culture slides, were treated with the indicated concentrations of DMF
for 14 hours. Then, the TUNEL assay was performed according to the manufacturer’s indications (bar¼ 50mm). (d) Effect of DMF on the caspase-3-like activity in
BAECs. Cells were plated in 96-well plates and treated with the indicated concentrations of DMF for 14 hours. Then, caspase 3/7 reagent was added to wells
according to the manufacturer’s instructions, and the luminescence was recorded at 30minutes with a microplate luminometer. Results are expressed as
mean±SD, *Po0.01, #Po0.05 versus control.
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cell growth. The observation that DMF is toxic for tumor cells
at concentrations at which it shows limited toxicity on normal
cells suggests a potential of this compound for tumor
treatment. This is in agreement with results reported for other
plant-derived antitumoral compounds and suggests that
metabolic and other stress conditions present in tumor cells
could probably make them more sensitive to those com-
pounds (Da Rocha et al., 2001).
Our results demonstrate for the first time that DMF inhibits
in a dose-dependent fashion certain functions of endothelial
cells, namely, differentiation, proliferation, and migration.
Inhibition of angiogenesis by DMF could not be explained by
a direct inhibition of the tyrosine kinase activity of VEGFR2,
as no effect was observed after in vitro incubation of the
recombinant VEGFR2 kinase with 200 mM DMF.
The antiangiogenic activity of DMF was first detected
using the in vitro differentiation assay for endothelial cells.
Our results show that DMF is a potent inhibitor of capillary-
like tube formation by BAECs or HUVECs at concentrations
that are lower than their respective IC50 values in the MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay. DMF also produced a dose-dependent inhibition of
another key step of the angiogenic process: the migratory
capability of endothelial cells. Although the little knowledge
we have about the pharmacokinetics of FAEs in humans
makes it difficult to extrapolate laboratory concentrations to
those achievable through oral administration, the concentra-
tions of DMF exhibiting an in vitro inhibition of angiogenesis
are in the range of concentrations used by other authors when
describing the in vitro activities of this compound. These
activities were not exhibited by similar concentrations of
MMF or FA, which is in agreement with previous results
showing that in most biological assays, DMF exerts pharma-
codynamic effects that are more potent than those of MMF
(Mrowietz and Asadullah, 2005).
The inhibition of fibroblast cell migration by DMF was less
efficient, suggesting a preferential effect of this compound on
the migratory capabilities of endothelial cells. Given that
Control DMF 100 nmol/CAM
Control DMF 25 µM
Figure 4. Dimethylfumarate (DMF) inhibits angiogenesis in vivo. (a) Chorioallantoic membrane (CAM) assay of DMF. (Left panel) Methylcellulose disc
containing the substance vehicle alone. (Right panel) Methylcellulose disc containing 100 nmol of DMF. Circles show the locations of the methylcellulose discs
(bar¼ 1,000 mm). (b) Transgenic TGfli1:EGFPy1 zebrafish embryos, which show green fluorescent protein (GFP) expression in endothelial cells, were incubated
without (left panel) or with 25 mM DMF (right panel). Blood vessel morphology was recorded by fluorescence microscopy (bar¼ 50 mm).
Table 1. Inhibition of in vivo angiogenesis by
dimethylfumarate (DMF)
Dose (nmol/CAM) Positive/total % Inhibition
CAM assay
0 0/20 0
50 1/4 25
100 3/6 50
200 7/10 70
400 5/6 83
Zebrafish assay
DMF (mM) Positive/total % Inhibition
0 0/30 0
5 7/30 23
10 19/24 80
25 23/26 92
In vivo chorioallantoic membrane (CAM) and live fluorescent zebrafish
embryo assays were carried out with different doses of DMF, as described
in the Materials and Methods section. Data are given as the percentage of
treated egg CAMs that showed inhibited angiogenesis or as the percentage
of treated zebrafish embryos that showed inhibited angiogenesis.
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previously reported results show contradictory effects of
DMF on the migratory activity of other cell lines (Yamazoe
et al., 2009; Valero et al., 2010), further experimental data
regarding the comparison of the effects of DMF on several
cell types and studies of the mechanisms leading to this
inhibition are needed to clarify this question.
Apoptosis is associated with characteristic morphological
changes, including chromatin condensation, nuclear frag-
mentation, cell shrinkage, plasma membrane blebbing, and
the formation of apoptotic bodies. Our studies on the nuclear
morphology of BAECs revealed that DMF induces nuclear
changes characterized by chromatin condensation and
nuclear fragmentation. This result was confirmed by monitor-
ing of the cell cycle distribution, showing an increase in the
percentage of cells with subdiploid DNA content; by TUNEL
assay, showing DNA fragmentation; and by measurement of
the activity of the effector caspase 3, showing activation of
the caspase proteolytic cascade after treatment with DMF.
Apoptosis induction was also observed by DMF treatment in
proliferating HUVECs, reinforcing the hypothesis that the
growth-inhibitory effect produced by DMF on proliferating
endothelial cells could be due, at least in part, to an induction
of apoptosis. Similarly, it has previously been reported that a
number of endogenous and exogenous angiogenesis inhibi-
tors do induce endothelial cell apoptosis, suggesting that
endothelial cell apoptosis induced by a variety of mechan-
isms might be responsible for inhibiting angiogenesis, thereby
preventing the growth of primary tumors and their metastases
(Lucas et al., 1998; Gururaj et al., 2002; Martı´nez-Poveda
et al., 2007). Our results show that DMF induces apoptosis in
proliferating endothelial cells, which could contribute to
the antiangiogenic potential of this compound, and they are
in agreement with the proapoptotic activity previously
described for DMF in other cell types (Kirlin et al., 1999;
Treumer et al., 2003; Mrowietz and Asadullah, 2005).
The proapoptotic activity of DMF was highly reduced in
nonproliferating endothelial cells, suggesting that DMF
treatment could mainly affect the newly formed rather than
the preexisting blood vessels and offering a possible
indication of the limited toxicity of this compound.
Inhibition by DMF of the mentioned essential steps of
in vitro angiogenesis agrees well with the observed effect on
in vivo angiogenesis, substantiated by using two widely
employed and independent experimental models: the chick
CAM and the live fluorescent zebrafish embryo neovascular-
ization assays. Our experimental data clearly show that
DMF is a potent inhibitor of angiogenesis in vivo, with these
activities being exhibited in a concentration-dependent
manner.
A remarkable number of plant-derived compounds have
been reported to inhibit angiogenesis in vitro and in vivo (Fan
et al., 2006; Bifulco et al., 2007; Varinska et al., 2010).
Although these have widely diverse structures, some com-
mon mechanisms are noted—in particular, inhibition of the
transcription factor NF-kB (De’ll Eva et al., 2007; Ichikawa
et al., 2007; Lin et al., 2007). Given the relevant role of
NF-kB in the control of angiogenesis (Huang et al., 2000), the
previously reported inhibition of NF-kB-mediated gene
transcription by DMF (Loewe et al., 2001 and 2002) could
contribute to the observed antiangiogenic effects of this
compound.
To our knowledge, the data presented here are the first
direct evidence showing the antiangiogenic activity of DMF.
Considering the putative role played by angiogenesis in the
development of psoriasis, these data could help to explain, at
least in part, the mechanism of action of the antipsoriatic
activity of FAEs. Because angiogenesis not only is needed
for the growth of primary tumors, but also has an essential
role in metastatic spread, the observed antiangiogenic
activity of DMF may also contribute to explaining the
observed antitumor and antimetastatic activity of DMF
(Loewe et al., 2006).
Taken together, the results presented in this study show
that FAEs inhibit angiogenesis in vitro and in vivo, affecting
several steps of the angiogenesis process. Our findings
identify DMF as the pharmacologically active compound
when compared with MMF or FA regarding angiogenesis
inhibition and could help to explain, at least in part, the
previously described antipsoriatic, antitumoral, and anti-
metastatic activities of this compound. Although additional
studies will be needed to elucidate the molecular mechan-
isms underlying the antiangiogenic activity of DMF, the data
presented here suggest its potential in therapeutic applica-
tions for the treatment of angiogenesis-related malignancies.
MATERIALS AND METHODS
Materials
Cell culture media were purchased from Biowhittaker (Walkersville,
MD). Fetal bovine serum was a product of Harlan-Seralab (Belton,
UK). Matrigel was purchased from Becton Dickinson (Bedford, MA).
Supplements, FAEs, and other chemicals not listed in this section
were obtained from Sigma Chemicals (St Louis, MO). Plastics for cell
culture were supplied by NUNC (Roskilde, Denmark).
Cell cultures
BAECs, isolated from bovine aortic arches (Ca´rdenas et al., 2006),
and HUVECs, isolated from human umbilical cords by collagenase
digestion (Kubota et al., 1988), were maintained as described
elsewhere (Martı´nez-Poveda et al., 2007 and Supplementary
Methods online). NIH3T3 fibroblasts and the cancer cell lines used
in this study (human fibrosarcoma HT1080, human colon adeno-
carcinoma HT29, human osteosarcoma U2-OS, and human breast
carcinoma MDA-MB-231) cells were obtained from the ATCC
(Rockville, MD) and maintained in culture as described by the
provider (Supplementary Methods online).
Cell growth assay
The MTT (Sigma Chemical) dye reduction assay in 96-well
microplates was used as previously described (Rodrı´guez-Nieto
et al., 2002 and Supplementary Methods online). IC50 values were
calculated as the concentrations of compound yielding 50% cell
survival, taking the values obtained for control as 100%.
Tube formation on Matrigel by endothelial cells
BAE and HUVE cells were seeded on Matrigel in the presence or
absence of the indicated concentrations of compounds as previously
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described by us (Martı´nez-Poveda et al., 2007 and Supple-
mentary Methods online). After 7 hours of incubation, cultures were
observed and photographed, and enclosed networks of complete
tubes from randomly chosen fields were counted and averaged.
Each group consisted of three or five Matrigels. For checking
the viability of endothelial cells after the treatment with DMF
in this assay, cells were incubated in 96-well plates in the
same conditions employed for the tube formation assay. After
7 hours, cell viability in comparison with control untreated cells was
determined by the addition of MTT essentially as described for the
cell growth assay.
Endothelial cell migration assay
The migratory activity of BAE, HUVE, and NIH3T3 cells was
assessed using a wounding migration assay. Confluent monolayers
were wounded and cells were supplied with complete medium
in the absence (controls) or presence of different concentrations of
FAEs. Wounded areas were photographed at different times of
incubation, and the amount of migration at 7 hours was determined
by image analysis in both controls and treated wells and normalized
to their respective values at zero time, using the NIH Image 1.6
software (developed at the U.S. National Institutes of Health and
available on the Internet at http://rsb.info.nih.gov/nih-image/)
(Martı´nez-Poveda et al., 2007 and Supplementary Methods online).
Apoptosis assays
After treatment with the indicated concentrations of DMF for
14 hours, apoptosis assays were carried out by staining of nuclei
with Hoechst, cell cycle analysis by flow cytometry, and TUNEL
assay as we have described elsewhere (Martı´nez-Poveda et al., 2007
and Supplementary Methods online).
For the determination of caspase 3/7 activity, Caspase-Glo 3/7
reagent (Promega Biotech Ibe´rica, Madrid, Spain) was used
according to the manufacturer’s instructions (Supplementary
Methods online).
In vivo CAM assay
The in vivo chicken CAM assay was carried out as described
elsewhere, using fertilized chick eggs provided by Granja Santa
Isabel (Cordoba, Spain) (Rodrı´guez-Nieto et al., 2002 and Supple-
mentary Methods online).
Zebrafish embryo assay
Zebrafish embryos were generated via natural pairwise mating and
maintained in embryo water at 28.5 1C. Transgenic fli-EGFP fish
(TGfli1:EGFPy1) had a vasculature labeled with GFP and were
purchased from the Zebrafish International Resource Center (ZIRC,
Eugene, OR) (Lawson and Weinstein, 2002). Embryos were manually
dechorionated with forceps at 24 hour postfertilization, arrayed in a
96-well plate (one embryo per well), and incubated with 100ml of
the indicated concentrations of DMF at 28.5 1C for 24 hours. DMSO
was used as both carrier of drugs and control. After incubation, fish
embryos were anesthetized with tricaine (0.02%), placed on slides,
and examined under an epifluorescence Nikon microscope
equipped with a DS-L1 Nikon (Chiyoda-Ku, Tokyo, Japan) digital
camera. Phenotypic changes were evaluated by two separate
observers. Movies of the flow of blood through the intersegmental
vessels were made 24 hours after incubation with the drugs, with a
LEICA DMIL inverted microscope (Leica Microsystems, Wetzlar,
Germany) at low and high magnification ( 4 and  20).
In vitro VEGFR2 kinase inhibition assay
VEGFR2 inhibition assay was performed using an HTScan VEGFR2
kinase kit (Cell Signaling Technology, Beverly, MA), combined with
colorimetric ELISA detection, according to the supplier’s instructions
(see Supplementary Methods online).
Statistical analysis
Results are expressed as mean±SD. Statistical significance was
determined using the two-sided Student t-test. Values of Po0.05
were considered to be statistically significant.
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